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Abstract
Acinetobacter baumannii is a significant pathogen in healthcare settings (specifically prominent in
healthcare- and ventilator-associated pneumonia) due primarily to its virulence and resistance to
a wide variety of antimicrobial drug classes, including carbapenems (CRAB). Existing therapies
(notably polymyxins, minocycline, tigecycline, amikacin, and sulbactam) often result in suboptimal
tissue concentrations, high rates of toxicity, and increasing rates of resistance. Although utilizing
combinations of antibiotics (specifically those containing colistin) have been employed, results have
been mixed, and control trials are lacking. Eravacycline is a novel tetracycline with an improved
pharmacokinetic profile and more potent activity against A. baumannii relative to tigecycline.
Cefiderocol has a unique mechanism of action that has performed well in vitro against multidrugresistant (MDR) and CRAB isolates. Limited clinical data exists with each of these agents. Other novel
antimicrobials are still in early phase clinical trials (ETX2514/sulbactam, TP-271, TP-6076, VNRX5133/cefepime, cefepime/zidebactam, AIC-499, GSK3342830, and SPR741) while further research
is underway for non-antibiotic approaches, specifically monoclonal antibodies and bacteriophage
therapies.
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Introduction
Acinetobacter baumannii is a non-motile, aerobic, Gramnegative opportunistic pathogen often causing serious, lifethreatening infections found most frequently in healthcareassociated infections (HAI), including ventilator-associated
pneumonia (VAP) [1]. Effective treatments for the management
of invasive A. baumannii infections are significantly limited
due to high rates of resistance to fluoroquinolones, tigecycline,
aminoglycosides, and β-lactams including carbapenems [2].
This is particularly notable in isolates associated with
HAI (up to 63% in one report) [3]. For these reasons, A.
baumannii has been identified together with other notable
nosocomial multi-drug resistant (MDR) organisms as an
ESKAPE pathogen (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pnemoniae, Acinetobacter baumannii,
Pseduomonas aeruginosa, and Enterobacter species) [4].
Due to the continued global rise in A. baumannii resistance,
in 2013 the Centers for Disease Control and Prevention (CDC)
declared MDR A. baumannii a serious threat [3]. Carbapenem
resistance in A. baumannii is independently associated with
increased hospital mortality and prolonged ICU and hospital
stays [6,7]. In 2017, the World Health Organization (WHO)
placed carbapenem-resistant A. baumannii (CRAB) on its
global priority list as a critical threat to promote and encourage
the research and development of new antibiotics [5,8].

Currently, there are a limited number of effective therapies
targeting this highly resistant pathogen [9]. The polymyxins,
minocycline,
tigecycline,
amikacin,
and
sulbactamcontaining agents are potential antimicrobial treatment
options, yet significant limitations exist for each agent.
These include increasing rates of resistance, inadequate
in vitro susceptibility testing methods, suboptimal tissue
concentrations, and toxicity profiles. Emerging treatment
options include the combination of “older” agents, new
antibiotics, and novel (non-antibiotic) therapies. It is
the objective of this review to describe the mechanisms,
epidemiology, and the current and developing management
strategies of invasive infections due to MDR A.baumannii.
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Mechanisms of Antimicrobial
Resistance
While definitions vary between sources, the term MDR most
often refers to in vitro resistance to 3 or more antimicrobial
classes, while extensively drug-resistant (XDR) is generally
used to describe resistance that excludes most standard
antimicrobial classes [10]. While MDR isolates may be
susceptible to a carbapenem in vitro, XDR A. baumannii is most
often carbapenem-resistant. For A. baumannii, pan-resistance

(PDR) describe isolates with in vitro resistance to all β-lactams
(including carbapenems), aminoglycosides, fluoroquinolones,
and polymyxins [10].

or aminoglycoside-modifying enzymes are key contributors to
quinolone and aminoglycoside resistance, respectively [15].

While not the most common of the ESKAPE pathogens, A.
baumannii is considered one of the most serious threats to
healthcare due to its extraordinary ability to quickly adapt
to selective environmental pressures (notably antibiotics)
[4,11,12]. Mechanisms of drug resistance are diverse and
include β-lactamase production, multidrug efflux pumps,
aminoglycoside-modifying enzymes, permeability defects, and
alteration in target binding sites [13,14]. These mechanisms
often work in tandem to convey resistance to multiple antibiotic
classes. Resistance may be a result of both vertical transfer
and its natural ability to integrate exogenous DNA into its own
genome [11].

Epidemology of MDR and XDR A.
baumannii Infections

Production of β-lactamases is generally considered to be
the most prevalent mechanism of antibiotic resistance in A.
baumannii. Each of the Ambler classes of β-lactamases (Class
A-D) have been isolated from A. baumannii, conferring
resistance to many commonly used β-lactam antibiotics [11]. In
addition to the intrinsic Class C β-lactamases, other serinedependent β-lactamases include Class A β-lactamases (TEM,
SHV, CTX-M, KPC, and others) that hydrolyze penicillin and
cephalosporins and Class D β-lactamases, oxacillinases (OXA).
Class D β-lactamases are the most prominent β-lactamase
conferring resistance to carbapenems via enzymatic degradation
with MDR isolates often containing more than one oxacillinase.
Class B β-lactamases, or metallo-β-lactamases (MBL), are
the broadest spectrum β-lactamase that hydrolyze almost all
β-lactams, including carbapenems. A number of MBL enzymes
have been recognized in A. baumannii including IMP, VIM, and
NDM [13,15].
In addition to β-lactamase production, other well-described
mechanisms contributing to MDR isolates include efflux
pumps, decreased permeability of the cell wall, and alterations
in target sites. Two efflux pumps, tet(A) and tet(B), are
tetracycline specific efflux pumps that confer resistance to
most tetracyclines, with the exception of tigecycline [16].
Tet(A) confers resistance to tetracycline, while tet(B) is highly
suggestive for minocycline resistance [11,17,18]. Multidrug
efflux pumps, such as AdeFGH and AdeABC, increase resistance
to many antibiotics, including carbapenems, tetracyclines,
and even tigecycline [11,15]. Interestingly, subinhibitory
concentrations of antibiotics due to low-dose treatment can
induce upregulation of the AdeFGH efflux pump, thereby
increasing biofilm formation [19]. The AdeABC efflux pump is
the most well-described multidrug efflux pump in A. baumannii
and effects β-lactams, aminoglycosides, tetracyclines,
fluoroquinolones, and others [11]. The AdeABC efflux pump
can also be upregulated when exposed to subinhibitory
concentrations. This mechanism may be most notable when
exposing A. baumannii to subinhibitory concentrations of
tigecycline, such as for treatment of bacteremia, as increased
minimum inhibitory concentrations (MICs) have been
found in vitro and likely contribute to poor clinical outcomes
[20]. A reduction in porin channels affecting membrane
permeability of many antibiotics have also been reported, while
a downregulation or alteration in lipopolysaccharides found
on the outer membrane of A. baumannii increases resistance
to colistin [21]. Finally, overexpression or alteration of target
sites via penicillin-binding protein (PBP) result in decreased
susceptibility of carbapenems, while the presence of GyrA

With the capabilities of forming biofilm and its propensity to
survive harsh, dry conditions, A. baumannii is a significant
hospital-acquired pathogen, particularly found in the
intensive care units (ICU) [22]. Risk factors for Acinetobacter
spp acquisition include receipt of broad-spectrum antibiotics
(specifically later generation cephalosporins), receipt and
duration of mechanical ventilation, ICU admission and duration
of stay, invasive procedures or devices, total parenteral nutrition,
and exposure to contaminated sources [1]. While most notable
for causing respiratory tract infections (including VAP), it has
also been reported to cause bloodstream infections (BSI), wound
or acute bacterial skin and skin structure infections (ABSSSI),
complicated urinary tract infections (cUTI), complicated intraabdominal infections (cIAI), and meningitis [1]. A. baumannii
has the propensity for biofilm formation, making it particularly
difficult to eradicate in certain conditions (notably on blood and
urinary catheters and endotracheal tubes) [23]. According to
the National Healthcare Safety Network (NHSN), A. baumannii
is the fifth most common VAP pathogen, accounting for 6.1% to
7.5% of all cases [24,25]. Despite only 2% of HAIs are caused
by Acinetobacter spp., crude mortality in patients with A.
baumannii infections can be as high as 75% [3,26].
Antimicrobial resistance in A. baumannii has demonstrated
notable increases in the last several years. For example, the
Meropenem Yearly Susceptibility Test Information Collection
Program demonstrated a 61% increase in meropenem resistance
over a 10-year period (1999-2008). Tobramycin maintained
the highest susceptibility rate over this period (59.1%) followed
by meropenem (45.7%), levofloxacin (33.9%) and ceftazidime
(31.5%) [2]. In a more recent global pooled prevalence study
assessing resistance in A. baumannii infections from countries
participating in the Organization for Economic Cooperation and
Development, a 55.7% meropenem resistance rate was reported
from 2006-2016. Meropenem resistance increased dramatically
from 25.7% in the years 2000 to 2005 compared to 55.6% from
2006 to 2010 and increased further to 70.1% from 2011 to
2016. Amikacin resistance increased from 38.2% to 43.6% to
66.6% over the same period, respectively [27].

Limitations of Established Monotherapy
Treatments for MDR A. baumannii
Polymyxins
Discovered over 70 years ago, use of the polymyxins (polymyxin
B and colistin) have reemerged due to the rise in MDR Gramnegative pathogens, including (but not limited to) CRAB. Use of
polymyxins is generally limited by a narrow therapeutic window,
with the most significant (often treatment-limiting) adverse
effects of nephrotoxicity and neurotoxicity (occurring in
6% to 55% and 7% to 27% of patients, respectively) [28,29].
Polymyxins are further restricted from widespread use in
invasive infections due to lack of optimal exposure targets in
critically ill patients and lack of reliable in vitro colistin testing
[30].
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Since colistin is administered as the inactive prodrug
formulation, colistin methanesulfonate (CMS), some
hypothesize that the delayed conversion to the active
form may result in reduced bacterial killing and promote
the development of treatment-emergent resistance or in
subsequent A. baumannii isolates [31-33]. When colistin MICs
to A. baumannii approach the susceptible breakpoint (< 2 μg/
mL, see Table 2), attaining adequate serum concentrations
in subjects with normal renal function is reported in only 3040% of patients receiving loading doses and at the maximum
recommended maintenance dose (capped due to increased
toxicity risks) [30,34]. Likewise, at the highest recommended
doses, polymyxin B is not consistently effective at achieving
optimal respiratory tract concentrations [30]. Furthermore,
rates of colistin resistance in respiratory isolates are increasing
[12,35]. The most concerning report of colistin resistance is
from a collection of VAP isolates from Europe. These isolates
demonstrated a 47.7% resistance rate with an MIC50/90
of 2 μg/mL and 256 μg/mL, respectively [12]. Previous
treatment with colistin is regarded as a significant risk factor
for the development of colistin heteroresistance, with colistin
resistance being associated with poor clinical outcomes [36-38].
This is most evident in a report of 19 patients infected with a
colistin-susceptible isolate and treated with intravenous CMS,
inhaled CMS, or both [37]. Colistin resistance was isolated in
all 19 patients after a median interval of 20 days. Of note, the
authors do not comment on the dosing of CMS. Retrospective
evaluations of colistin monotherapy versus a monotherapy
comparator agent (ampicillin/sulbactam) in the treatment
of mixed CRAB infections demonstrated increased 30-day
mortality and mortality during therapy in the colistin cohorts
[39,40]. In a prospective evaluation of 28 MDR A. baumannii
VAP patients treated with colistin or imipenem-cilastatin,
clinical efficacy was similar among cohorts (60.0% vs 61.5%)
[41]. Efficacy data for the use of monotherapy polymyxins for
MDR A. baumannii remain scarce with contrasting outcomes.
Irrespective of the preceding limitations, polymyxins remain
as a primary treatment option for MDR A. baumannii with the
majority of clinical data surrounding polymyxins as combination
therapy.
Minocycline
Minocycline is yet another agent with a recent resurgence due to
carbapenem- resistant Gram-negative infections, most notably
CRAB. Following a brief hiatus, intravenous minocycline
was re-introduced to the market in 2009 and is accompanied
with an FDA-approved indication for infections caused by
Acinetobacter spp. In vitro data suggests minocycline may
play a role in the treatment of infections involving prosthetic
material. In one study, minocycline prevented biofilm formation
in 96% of biofilm-forming A. baumannii isolates [42]. In vitro
susceptibility of A. baumannii to minocycline ranges from 70.3%
to 79.1% in highly carbapenem-resistant isolates (meropenem
susceptibilities ranging from 8.7% to 36.4%) [16,43,44]. In
contrast, only 37.8% of 200 carbapenem-resistant isolates
were minocycline susceptible in one report [45]. The majority
of minocycline resistance (71.1%) in A. baumannii was due to
the presence of the tet(B) clinical strains, whereas when this
efflux pump was absent, only 6.7% of isolates were resistant
[18]. Clinical success rates in CRAB VAP patients treated with
minocycline are high (> 80%), yet clinical data are extremely
limited and generally associated with combination therapy [46].
Tigecycline
Tigecycline, a glycylcycline, is a semisynthetic derivative

of minocycline that is able to overcome most tetracycline
resistance mechanisms. Pharmacokinetic limitations, risk of
treatment-emergent failure, and higher mortality (compared
to imipenem-cilastatin) in HAP/VAP treated patients limit
its widespread use [11,47]. Currently, no Clinical Laboratory
Standards Institute (CLSI)-approved breakpoints for tigecycline
against A. baumannii exist, and (as expected) variability
in testing methods have produced inconsistent in vitro
susceptibility results [48,49]. Although worldwide surveillance
studies show that the MIC90 against MDR A. baumannii isolates
has remained at 2 μg/mL, treatment-emergent resistance has
occurred in various case reports at standard dosing [44,50] .
This is thought to be a result of suboptimal concentrations of
tigecycline (notably in the treatment of bacteremia) combined
with overexpression of efflux pumps [20,32,50]. Clinical data
concerning tigecycline treatment, often in combination, are
not promising as higher rates of in-hospital mortality were
observed [51]. Due to these limitations, tigecycline’s current
role is generally restricted to the treatment of colistin-resistant
isolates or as part of combination therapy to prevent the
emergence of colistin resistance or heteroresistance.
Amikacin
The emergence of resistance to all aminoglycosides is due
to the production of aminoglycoside-modifying enzymes or
efflux pumps mechanisms in MDR A. baumannii strains [11].
Amikacin is an aminoglycoside used in the treatment of A.
baumannii infections since it often retains in vitro susceptibility
to CRAB isolates. However, resistance rates to amikacin have
been on the rise [27]. In one report, less than 20% of CRAB
isolates maintained susceptibility to amikacin [52]. Treatmentemergent resistance to amikacin has also been shown to
develop [53]. Clinical studies evaluating amikacin monotherapy
against A. baumannii infections are lacking.
Sulbactam-containing regimens
Sulbactam, a class A β-lactamase inhibitor, has intrinsic in
vitro activity against A. baumannii and exhibits high-affinity
for penicillin-binding proteins (notably types 1a and 2) [54].
However, resistance to sulbactam-containing combinations
(such as ampicillin or cefoperazone) has dramatically increased
with MICs often > 16 μg/mL. One study reports ampicillinsulbactam resistance rates at 72.3% in the years 20112016 [27]. In another report, rates of ampicillin/sulbactam
susceptibility to carbapenem-susceptible strains was 94.1%, yet
when tested against the carbapenem-resistant phenotype, only
19.4% remained susceptible [45].
For these reasons, the majority of sulbactam-containing studies
in the treatment of A. baumannii have been in combination with
other therapies. In a pooled analysis of 13 studies, including one
prospective study, sulbactam-containing combination regimens
were similar in terms of clinical response, bacteriological
response and in-hospital mortality compared to the control
group. When analyzing for dose, the high-dose regimen
(sulbactam > 9 g/day) was found to be more effective and was
well tolerated without serious adverse effects [55]. High-dose
sulbactam- containing regimens may be a suitable treatment
option for CRAB at an MIC ≤ 4 μg/mL to preserve other
therapies and better safety profile.

Combination Therapies
The vast majority of data surrounding combination therapies
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Table 1. In vitro activity of select therapies against carbapenem-resistant A. baumannii isolates
Novel Therapy
Eravacycline

Cefiderocol

ETX2514SUL

TP-6076

Number of CRAB
isolates

MIC50
(μg/mL)

MIC90
(μg/mL)

MIC Range
(μg/mL)

Reference

286

0.5

1

< 0.06 to > 64

[82]

707

1

2

0.06 to 8

[158]

52

0.5

2

< 0.016 to 4

[159]

193

1

2

0.12 to 8

[119]

595 (EU)

0.12

1

0.004 to 64

[101]

173 (NA)

0.25

1

< 0.002 to 8

[101]

562

0.5

2

< 0.002 to > 256

[102]

100

0.5

8

0.06 to > 64

[103]

768

0.12

1

< 0.002 to 64

[104]

107

0.06

0.5

< 0.03 to 2

[105]

44

0.12

1

0.012 to 4

[160]

731

1

4

< 0.06 to 32

[54]

72

1

2

N/A

[109]

121

0.03

0.06

< 0.002 to 0.12

[117]

326

0.06

0.125

0.008 to 0.5

[119]

41

0.008

0.063

0.002 to 0.25

[108]

EU: Europe; NA: North America; MIC50: minimum inhibitory concentration at which 50% of isolates are inhibited; MIC90: minimum inhibitory concentration
at which 90% of isolates are inhibited; CRAB: carbapenem-resistant Acinetobacter baumannii

Table 2. In vitro susceptibility testing of select therapies for A. baumannii isolates [34].
Antimicrobial Agent

Interpretive Categories and
MIC breakpoints (μg/mL)
S

Colistin

I

<2

Comments

R
>4

•
•

Minocycline

<4

8

> 16

Tigecycline

-

-

-

Amikacin

< 16

32

> 64

Ampicillin/sulbactam

< 8/4

16/8

> 32/16

Meropenem

<2

4

>8

Eravacycline

-

-

-

Omadacycline

-

-

-

<4

8

> 16

Cefiderocol

BMD is only approved MIC testing method; disk diffusion
and gradient diffusion methods should not be performed
Predicts MIC to polymyxin B

•

A. baumannii that are susceptible to tetracycline predicts
susceptibility to minocycline. If intermediate/resistant to
tetracycline, susceptibility to minocycline cannot be assured

•

Breakpoints are based on a dosage regimen of 1 g administered every 8 h or 500 mg administered every 6 h

•

Breakpoints based on a dosage regimen of2 g every 8 h
administered over 3 h
Testing cefiderocol required iron-depleted cation-adjusted
Mueller-Hinton broth (CAMHB). Chelation is used for iron
depletion, which removes other cations (calcium, magnesium, and zinc). Following this process, cations are added
back to concentrations of calcium 20-25 mg/L, magnesium
10-12.5 mg/L, and zinc 0.5-1.0 mg/L

•

MIC: minimum inhibitory concentration; S: susceptible; I: intermediate; R: resistant; BMD: broth microdilution
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of A. baumannii treatment are in patients with pneumonia
or mixed infections. Polymyxin-based therapies were most
commonly studied (> 50%), while tigecycline-based therapies
were the next most frequent (25%) [34].
Several in vitro studies have shown synergistic effects of colistin
in combination with sulbactam, tigecycline, carbapenems,
glycopeptides, and others [56]. In addition, combination
regimens may improve microbiological cure rates (when
compared to monotherapy), yet has rarely translated to
improved clinical outcomes, specifically reductions in mortality
[57]. To date, five prospective trials have evaluated colistinbased regimens combined with rifampin, fosfomycin (twice),
ampicillin- sulbactam, and meropenem for MDR Gramnegative bacteria, primarily A. baumannii [58-62]. When these
data are combined, colistin combination therapy showed
no difference for in-hospital morality and clinical response.
Only the combination with ampicillin/sulbactam (n=39) was
associated with a favorable clinical response compared to
colistin monotherapy, whereas the remaining studies showed
no difference for in-hospital mortality and clinical response
[60,63]. While polymyxin-based therapies appear to offer
no additional benefit over monotherapy groups, significant
limitations to the available data remain. These include high
mortality or treatment failure regardless of treatment,
documentation of time to appropriate therapy, use of colistin
rather than polymyxin B in invasive infections, and suboptimal
reporting of MICs, dosing regimens, and use of concomitant
antibiotics [30].
The majority of data for tigecycline-based combination therapies
are limited to retrospective data in pneumonia treated patients,
mainly VAP, and clinical outcomes are not promising. In two
retrospective studies evaluating tigecycline monotherapy (100
mg IV loading dose, then 50 mg IV q12h) versus tigecyclinebased combination therapy (multiple agents), there was
no difference in clinical success, mortality, or microbiological
outcomes [64,65]. Similarly, when evaluating tigecycline-based
combination therapy versus non-tigecycline-based combination
therapy, clinical cure and mortality outcomes were similar
[66-69], while microbiological eradication with tigecyclinebased therapy was significantly lower in one trial [67]. In a
more recent evaluation of 238 adult ICU patients with CRAB
pneumonia, those treated with tigecycline-based combination
therapies had higher ICU mortality than non-tigecycline
therapy (adjusted odds ratio 2.30, 95% confidence interval
1.19-4.46) [70]. When the data are combined, treatment with
tigecycline for MDR A. baumannii is associated with higher
in-hospital mortality and trended towards a longer hospital
stay; however, monotherapy versus combination therapies
did not show the same difference [51]. While the data for
tigecycline-combination therapies has obvious limitations,
there seems to be no additional benefit of combination therapy
with tigecycline.
Data regarding use of minocycline combination are also
sparse. A retrospective review of 36 VAP patients with CRAB
isolates and treated with minocycline/doxycycline found a
clinical response rate of 81.8% (n=11) for the monotherapy group
and 80.0% (n=25) in those receiving minocycline-combination
therapy [46]. Another retrospective review demonstrated
a clinical success rate of 40/55 (73%) in patients treated
with minocycline for MDR A. baumannii infection of various
types. Of those 55 patients, only three received treatment with
minocycline monotherapy while 52 received combination with

another active agent [71]. While doses utilized in these studies
ranged from 200-400 mg daily, one study suggests utilizing
high dose minocycline (e.g. 700 mg daily) or as combination
therapy to prevent rapid emergence of resistance [5]. However,
the safety and tolerability of such regimens has not been
established.

Pharmacokinetic / Pharmacodynamic
(PK/PD)-Based Dosing
With the rising of resistance rates of A. baumannii and the
lack of new antimicrobials to the marketplace in recent years,
clinicians have pursued optimizing the dosing of existing agents
based on their PK/PD properties. This includes utilizing higher
doses, shortening the dosing interval and prolonging infusion
times. Each of these principles may be applied to β-lactams
(eg, carbapenems, ampicillin/sulbactam) as they demonstrate
a time-dependent antibacterial activity with maximal
bactericidal effects occurring at serum concentrations
approximately four times the MIC of the pathogen for at least
40% of the dosing interval [72]. Additionally, greater clinical
cure and bacteriological eradication is achieved if the free drug
concentration remains above the MIC of the pathogen for 100%
of the dosing interval in critically ill patients [73].
While high-quality efficacy data are limited with this
approach, β-lactam agents are generally well tolerated without
an increased risk of toxicity when intermittent infusions were
compared to prolonged infusion strategies. In the largest
of these randomized control trials (all pathogens n=214,
Acinetobacter spp. n=20), continuous infusion meropenem
had a similar clinical cure rate when compared to intermittent
dosing [74]. Higher microbiological success rates, shorter ICU
lengths of stay, and shorter durations of meropenem therapy
were observed with no difference in safety outcomes. In a
meta-analysis comparing prolonged infusions to intermittent
bolus doses of meropenem, the prolonged infusion cohort
had higher rates of clinical success (OR 2.10, 95% CI 1.313.38) and lower mortality (RR 0.66, 95% CI, 0.50-0.88) [75].
In the single study evaluating 30 HAP patients with MDR A.
baumannii isolates, no difference in clinical efficacy or relapse
rates were observed among cohorts [76]. Of note, doripenem
is the lone carbapenem that should not utilize prolonged
infusions, as higher mortality rates were seen among patients
with microbiologically confirmed late-onset VAP [77].
To overcome suboptimal tigecycline concentrations, a phase
II study and a retrospective analysis demonstrated higher
tigecycline doses (100 mg IV every 12 hr) in VAP-treated
patients were associated with improved clinical cure rates
compared to standard doses without increases in adverse
events [78,79]. While higher doses may be warranted in severe
infections (eg, pneumonia), clinical data are limited due to early
termination of the phase II study due to poor recruitment.

Newly Approved Therapies
Eravacycline
Eravacycline (Xerava™) is a novel, fully synthetic fluorocycline
antibiotic approved by the FDA in August 2018. Similar to
other tetracycline derivatives, it inhibits bacterial protein
synthesis by binding to the 30S ribosomal subunit [80].
Eravacycline is structurally similar to tigecycline, except it has
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two modifications to the D-ring core at C-7 and C-9 [80]. These
modifications enhance its antibacterial spectrum of activity and
its stability against tetracycline- specific resistance mechanisms
(e.g. efflux pumps and ribosomal protection proteins) [81].

respectively, while 71.2% of isolates were inhibited at an MIC
of < 4 μg/mL. Additionally, in the 293 tetracycline resistance
strains, the MIC50/90 values were unchanged, although only
57.3% of strains were inhibited at 4 μg/mL [93].

Eravacycline demonstrates a broad spectrum of activity in
vitro against aerobic and anaerobic Gram-positive and Gramnegative pathogens, including MDR A. baumannii [80,8284]. The MIC50/90 were 0.06/0.5 μg/mL and 0.5/1 μg/
mL(respectively) against A. baumannii isolates from patients
in 13 Canadian hospitals and 11 hospitals in New York
[81,84]. Another study reported MIC50/90 values against
CRAB isolates of 0.5 μg/mL and 1 μg/mL, respectively (Table
1) [82]. In two in vitro studies, 89% and 96% of CRAB isolates
had eravacycline MICs of ≤ 1 μg/mL [82,83]. When compared
to tigecycline, eravacycline has been shown to be two- to fourfold more potent than tigecycline against A. baumannii isolates,
including carbapenem-resistant isolates [81-84].

Omadacycline was granted FDA approval in October 2018 for
the treatment of community-acquired bacterial pneumonia
(CABP) and ABSSSI [73]. In two randomized controlled
trials, OPTIC and OASIS-1, treatment with omadacycline
was noninferior for early clinical response when compared to
moxifloxacin and linezolid, respectively [94,95]. However,
both trials failed to include MDR Gram-negative pathogens,
including A. baumannii. While studies are nearing
completion for cystitis and pyelonephritis, it is unlikely that
these will provide any useful data to its clinical utility in the
treatment of A. baumannii.

The efficacy of eravacycline has been evaluated in several Phase
II and III studies for the management of cIAI and cUTIs [85-88].
Despite these numerous studies, efficacy relating to infections
caused by A. baumannii is limited. In a pooled analysis of the
IGNITE 1 and 4 studies, the clinical and microbiological response
rates were 100% for patients with A. baumannii, including
MDR isolates [89]. Of note, IGNITE 1 only had 8 patients and
IGNITE 4 had 5 patients with A. baumannii infections [85,90].
In contrast, the efficacy of eravacycline in cUTIs has not been as
promising [88,91]. Eravacycline is eliminated predominately in
the feces (with low urinary excretion), suggesting eravacycline
may not be an effective treatment option for UTIs caused by
MDR A. baumannii.
Eravacycline has been well-tolerated in clinical studies and
most adverse events have been similar to comparator agents
with a few exceptions. Notably, the reported incidences of
infusion site reactions, nausea, and vomiting have been higher
compared to carbapenems [80]. Despite higher incidences of
nausea and vomiting compared to carbapenems, they are still
significantly lower than those reported with tigecycline (6.5%
vs 26% and 3.7% and 18%, respectively) [44,80]. One potential
disadvantage of eravacycline compared to other therapies
for MDR A. baumannii is the concern for drug interactions.
Eravacycline is a substrate for the CYP450 enzyme system,
specifically CYP3A. When administered concomitantly with a
strong CYP3A inducer (e.g. rifampin), the dose of eravacycline
should be increased to 1.5 mg/kg IV every 12 hours. There
are no formal recommendations regarding eravacycline and
strong CYP3A inhibitors at this time. Additionally, eravacycline
has the potential to increase the effects of warfarin, thus dose
adjustments may be warranted [80].
Omadacycline
Omadacycline (NUZYRA™) is a semisynthetic derivative of
minocycline and is a novel aminomethylcycline antibiotic. Much
like eravacycline, omadacycline has the ability to remain active
in the presence of tetracycline efflux and ribosomal protection
genes resulting in a broad spectrum of activity [92].
In vitro omadacycline data against a collection of 2101
worldwide clinical isolates of A. baumannii demonstrated an
MIC50/90 of 2 μg/mL and 4 μg/mL, respectively, with 91.5% of
isolates inhibited at MIC values < 4 μg/mL [92]. In a collection
of 441 A. baumannii isolates from 2016, omadacycline
MIC50/90 values were slightly higher at 4 μg/mL and 8 μg/mL,

Agents Undergoing Phase I-III Clinical
Trials in the US
Cefiderocol
Cefiderocol (previously S-649266) is a parenteral siderophore
cephalosporin currently in phase III clinical trials for the
treatment of nosocomial pneumonia and other severe infections
caused by Gram-negative pathogens [96,97]. Cefiderocol has
a unique catechol moiety at the C-3 position contributing
to its mechanism of action, ability to chelate with ferric iron,
and ultimately bacterial cell entry. Termed a “Trojan
horse” antibiotic through a strategy of exploiting the iron
transport mechanism of bacteria, the siderophore-drug
complex selectively interacts with the siderophore receptors
on the bacterial cell surface to be actively transported across
the outer membrane. Due to this mechanism, this novel
antimicrobial is able to circumvent permeability-mediated
drug resistance [98,99]. The halogenated catechol group
along with the quaternary amine at the C-3 position produces
increased in vitro activity when certain MBLs, KPC and OXA
producing strains are present [100].
Cefiderocol demonstrates potent in vitro activity in isolates
tested against a broad range of ESBL-producing Gramnegative organisms, including MDR and XDR P. aeruginosa
and A. baumannii (susceptible breakpoint of 4 μg/mL, see
Table 2), with negligible activity against Gram-positive aerobic
and anaerobic bacteria [98]. When tested against 1148 A.
baumannii isolates from North America and Europe, the MIC90
value for cefiderocol was 1 μg/mL. When evaluated against
CRAB, cefiderocol retained an MIC90 of 1 μg/mL and 96.9%
(744/768) of meropenem-nonsusceptible isolates had MICs of
< 4 μg/mL [101]. Other studies confirmed this potent activity
against CRAB isolates ranging from 88% to 96.9% with MICs
of < 4 μg/mL [102-104]. With regard to colistin-nonsusceptible
strains of A. baumannii (n=121), cefiderocol’s MIC range was <
0.002 to 8 μg/mL with an MIC90 of 2 μg/mL [101]. In another
study comparing colistin-resistant strains versus colistin nonresistant strains, the MIC range of cefiderocol did not differ
[105]. When evaluating specific carbapenemase enzymes, there
does not appear to be a correlation of carbapenemase production
and cefiderocol resistance [104]. Of note, the mechanisms
conferring elevated MICs are currently being evaluated [104].
Cefiderocol has been well tolerated in phase I and II studies with
its safety profile being similar to that of other cephalosporins
[106,107]. Most adverse events have been gastrointestinal
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related (diarrhea, constipation, nausea, vomiting) while
occurring less frequently than the comparator agent (12%
vs 18%, respectively) [107]. Cefiderocol is a β-lactam with a
chemical structure most closely related to cefepime. Allergic
reactions are possible, however, only one patient discontinued
treatment due to urticaria during the infusion. This adverse
event was deemed not to be an antibody-mediated reaction
[106].
To date, the efficacy of cefiderocol has been evaluated in
one completed Phase II trial. This study included 452 patients
for the treatment of cUTI at risk for MDR Gram-negative
uropathogens, primarily E. coli and K. pneumoniae (no A.
baumannii isolates noted), compared to high-dose imipenemcilastatin. Cefiderocol met the noninferiority primary endpoint
of the composite of clinical and microbiological outcomes at the
test-of-cure (73% vs 55%, p=0.0004) and achieved superiority
in the post-hoc analysis [107].
Two phase III clinical trials focusing on the treatment of invasive
MDR pathogens are currently enrolling patients [96,97]. The
CREDIBLE-CR trial (NCT02714595) is estimated to enroll
150 patients to compare cefiderocol to best available therapy
(a polymyxin-based or non-polymyxin based regimen) for the
treatment of severe infections (BSI, HAP/VAP, cUTI, sepsis)
caused by CR Gram-negative pathogens [96]. The APEKS-NP
trial (NCT03032380), is estimated to enroll approximately 300
patients to compare 14-day all-cause mortality with cefiderocol
versus meropenem (both in association with linezolid) in adults
for the treatment of nosocomial pneumonia caused by Gramnegative pathogens [97].
ETX2514 + sulbactam (ETX2514SUL)
ETX2514, a novel diazabicyclooctane β-lactamase inhibitor,
also has intrinsic activity to Enterobacteriaceae and also
has the ability to fully restore sulbactam’s activity against
A. baumannii while protecting against all serine-dependent
β- lactamases (Class A, C, and D) [108]. In a globally diverse
collection of A. baumannii isolates (n=1131), the in vitro activity
of ETX2514SUL was 16-fold more active than sulbactam alone
(MIC90 4 μg/mL vs 64 μg/mL, respectively) [54]. Additionally,
ETX2514SUL retained the same activity when subsets of
meropenem-resistant (Table 1), colistin-resistant, and MDR
isolates were evaluated, while there was reduced activity
against one isolate containing an MBL [54]. Similarly, a
study of 72 A. baumannii isolates with the majority being
MDR isolates, had an MIC90 of 2 μg/mL [109]. Spontaneous
resistance has not been observed and the use of this agent
has not resulted in the generation of resistant β-lactamases to
ETX2514SUL [110].
One phase II study has been completed with positive results
[111]. This phase II double-blind, placebo-controlled trial of
80 patients compared ETX2514SUL (1g/1g q6h for 7 days)
plus imipenem-cilastatin to imipenem-cilastatin plus placebo
in adult patients with cUTI including acute pyelonephritis.
Outcomes were similar between the two groups. In an
exploratory analysis, eight patients had imipenem-nonsusceptible pathogen resulting in microbiological eradication
in 3/3 (100%) in the ETX2514SUL plus imipenem-cilastatin
cohort vs 3/5 (60%) patients in the imipenem-cilastatin plus
placebo cohort. Entasis Therapeutics plans to initiate a Phase
III study focused on CRAB infections in the first quarter of 2019
[111].

TP-271
TP-271 is a novel, fully-synthetic fluorocycline antibiotic under
the development by Tetraphase Pharmaceuticals for treatment
of CABP, pneumonic tularemia, and other serious respiratory
bacterial/bio threat infections [112,113]. When the most
common tetracycline-specific mechanisms are present, efflux
pumps and ribosomal protection proteins, TP271 remains
active in vitro [114]. When evaluated against four CRAB
isolates in a neutropenic lung mouse model, TP271 was dosedependent with area under the curve (AUC) to MIC ratio best
correlating with efficacy. This study supported the future
research in respiratory infections including A. baumannii
infections. A phase I study of escalating doses was well tolerated
with gastrointestinal symptoms being most frequently reported
[112]. Additionally, there are two ongoing phase I studies
assessing single and multiple ascending doses of an oral
formulation [115,116].

TP-6076
Another novel, fully synthetic tetracycline is currently
in phase I studies. It has a similar mechanism of action to
tetracyclines in which it disrupts bacterial synthesis by binding
to the 30S ribosomal subunit. In vitro data have shown potent
activity against CRAB isolates with many containing OXA and
OXA-like β-lactamases [117-120]. In the largest of these studies
with 326 global isolates from the years 2005-2016, TP-6076
had MIC50 and MIC90 values of 0.06 μg/mL and 0.125 μg/
mL while eravacycline had values of 0.5 μg/mL and 1 μg/mL,
respectively (Table 1) [119]. TP-6076 did not demonstrate
higher MIC values when comparing colistin-susceptible and
non-susceptible isolates. However, the MIC90 was one dilution
lower for tigecycline- and minocycline-susceptible and nonsusceptible isolates [117]. In isolates overexpressing genes
encoding the AdeABC multidrug efflux pump, the major
contributor to tigecycline resistance, TP-6076 had an MIC
range of 0.008 to 0.13 μg/mL [118]. Gastrointestinal events
(nausea and vomiting) were the most frequently reported
adverse event with higher rates at the higher doses [121]. A
second phase I study is currently recruiting to assess
the safety and bronchopulmonary PK with a dose of 30 mg
daily [122]. With very little data, it seems as if TP-6076 is
minimally impacted by the major resistance mechanisms of
the tetracycline class with MICs mostly unaffected by serinedependent β-lactamases.
VNRX-5133 + cefepime
Combined with cefepime, VNRX-5133 is a cyclic boronate
β- lactamase inhibitor with broad-spectrum activity against
serine- (classes A, C, and D) and metallo-β-lactamases (VIM/
NDM, class B). This combination agent is primarily being
explored for CRE and CR Pseudomonas aeruginosa. In vitro
data describes VNRX-5133/cefepime as a highly active agent
against Enterobacteriaceae and P. aeruginosa that is resistant
or has evolved resistance to other β-lactam/ β-lactamase
inhibitors, however, its use against A. baumannii has not been
described [123].
Zidebactam (WCK 5107), WCK 5153, cefepime/zidebactam
(WCK 5222)
Zidebactam (WCK 5107) and WCK5153 are novel non-βlactamase bicyclo-acyl hydrazide β-lactam enhancer antibiotics
that are under development for MDR Enterobacteriaceae,
P. aeruginosa, and CRAB [124]. These novel agents have a
dual mechanism of action where they enhance β- lactams
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through complementary high-affinity binding to PBP2 while
strongly inhibiting class A and C β-lactamases along with
modest inhibition of Class D β-lactamases. When zidebactam
is combined with cefepime (WCK 5222) in vitro against 5946
Enterobacteriaceae isolates, the combination demonstrated
potent activity even against CR isolates. However, the MIC
range of 639 A. baumannii isolates was 0.06 μg/mL to > 64
μg/mL with only 44.3% of isolates having a MIC < 8 μg/mL
[125]. These are less than optimal in vitro results against A.
baumannii isolates, yet in vivo activity against OXA-23 or OXA24 isolates in a neutropenic thigh model and lung infection
model showed greater than expected results [110,126].
WCK 5222 has been well tolerated in Phase I studies in subjects
with both normal and impaired renal dysfunction [127,128].
Both agents are highly renally eliminated and will require dose
adjustments based on the severity of dysfunction [127]. The
pharmacodynamic property predicting therapeutic response for
WCK 5222 is the free drug concentration in plasma exceeding
the MIC over the dosing interval (Tf > MIC). In subjects with
normal renal function receiving multiple doses of either 2 g/1
g or 2 g/2 g of cefepime/zidebactam, AUC and maximum
serum concentration (Cmax) were dose proportional, no
accumulation occurred, and no pharmacokinetic interaction
was observed when co-administered [128]. Phase I studies
evaluating plasma and lung tissue provided data to support the
use of WCK 5222 in the treatment of pneumonia, while other
organ systems have yet to be evaluated [129].

Other Antibiotics
AIC-499 (BL) + unknown BLI
AIC499 is termed as an innovative β-lactam antibiotic and is
combined with a currently unspecified β-lactamase inhibitor.
According to the drug developer’s website, AIC499 shows
potent activity against many Gram-negative pathogens
including MDR P. aeruginosa and A. baumannii for use in
cUTI and cIAI. Phase I studies were expecting results in 2017
with plans for future phase II studies, however, no trials are
currently registered on multiple government trial registries.
The phase I study was to be a single dose study in 48
healthy subjects immediately followed by a multiple ascending
dose study in 36 subjects at the Medical University of Vienna,
Austria. The Innovative Medicines Initiative with the
COMBACTE-MAGNET project is supporting AiCuris in the
clinical development of AIC499 [130].
GSK3342830 (GSK830)
GSK3342830 or GSK830 is a catechol-cephalosporin with a
spectrum of activity similar to that of the other siderophore
cephalosporin, cefiderocol [131]. In vitro data are promising
against A. baumannii with 94 MDR global isolates having
MIC50 and MIC90 of 0.06 μg/mL and 0.6 μg/mL, respectively
[131]. However, a phase I dose-escalation study was stopped
early. It is important to note that 35.7% of subjects discontinued
the study drug during the multi- dose arm due to fever,
headache, malaise or transaminitis [132].
SPR741 (formerly NAB74)
SPR741 (formerly NAB74) is a polymyxin-B-like molecule
being developed as an antibiotic adjuvant for the treatment
of XDR A. baumannii. This molecule does not have certain
structural features of the polymyxins that contribute to their
nephrotoxicity, however, this agent has minimal intrinsic

activity against A. baumannii and must be used as combination
therapy [133]. When combined with rifampin in pre-clinical
data of a murine pneumonia model, this combination has
shown to be effective in reducing bacterial burden (suggesting
utility in A. baumannii lung infections) [133,134]. SPR741 has
a short half-life of approximately 3 hours with 50% of the drug
excreted in the urine within one-hour post-dose with no evidence
of accumulation with 400 mg administered intravenously
every 8 hours [135]. Other phase I studies have been completed
in 2017; however, no results are available [136,137].

Novel Therapies
Monoclonal antibodies
Antibacterial monoclonal antibodies (MAbs) have the ability
to protect (e.g., palivizumab for prophylaxis against respiratory
syncytial virus) and treat (e.g., obiltoxaximab for treatment
of inhalational anthrax) against deadly infections. MAbs
are highly specific and may lessen the disruption of normal
gastrointestinal flora with less selective pressure for crossresistance with antibiotics [138]. Additionally, antibacterial
MAbs could have an enormous impact on controlling
institutional outbreaks once the pathogen is known. However,
aside from their narrow spectrum, there are concerns
surrounding the use of MAb therapy in infectious diseases.
Notably, these include high cost, complex administration, and
barriers to MAb development [139].
Several studies have shown MAb efficacy against A. baumannii
in mice when provided as active immunization (i.e., vaccine)
and passive immunization in various models [140-143]. Most
recently, a MAb, C8 in an A. baumannii mice pneumonia and
sepsis model demonstrated enhanced bacterial clearance,
prevented progression to septic shock, and had synergistic
activity with colistin. An area of concern in this study was the
ability of C8 to bind to only 60% of A. baumannii strains tested
[144].
Phage therapy
As A. baumannii resistance continues to increase and the
portfolio of antibiotics is becoming increasingly less effective,
bacteriophage therapy becomes an alluring option. Termed
“phage,” this technology is simply a virus engineered to infect a
pathogenic bacterium, replicate inside the host cell, and finally
rupture the bacterial cell wall resulting in cell death [145].
Similarly to MAbs, phage are highly specific, infecting only
prokaryotic cells resulting in minimal toxicities and side effects
[146]. Additionally, their mechanism of action is completely
independent of antibiotics so their efficacy is not altered
against highly resistant bacteria [147]. Other advantages of
this technology include the potential for combinations with
traditional therapies [148]. However, numerous questions about
this therapy remain. This therapy is not currently recognized as
a drug and a clear lack of regulatory framework exists [145,149].
Because it is given in high quantities, the human body may
recognize phage as foreign antigens, produce antibodies,
and theoretically result in a diminished activity. Finally, the
possibility of horizontal gene transfer can occur resulting in
the transfer of resistance genes and virulence factors between
bacterium and phage [146].
Numerous studies (n=30) with a total of 1,152 patients have been
conducted to evaluate the efficacy and safety of phage therapy
against ESKAPE pathogens. Of the 30 studies, 87% showed

ULJRI Vol 3, (2) 2019

8

efficacy of reducing bacterial growth with successful outcomes.
Twenty-two studies reported on the safety profile with only two
reporting side effects after phage treatment [147]. Regarding
A. baumannii specific infections, several animal models have
been conducted in MDR and CRAB isolates with promising
results [150-155]. To date, only two human case reports of
phage therapy directed against MDR A. baumannii have been
published [156,157]. The first describes a case of a 68-year-old
diabetic patient with necrotizing pancreatitis complicated by an
MDR A. baumannii infection. In conjunction with combination
antibiotics, three phage cocktails were provided intravenously
and percutaneously into the abscessed cavity in repeated daily
intervals for a total of 59 days. The patient’s initial status was
improved after commencing phage therapy with an eventual
return to health. Interestingly, however, subsequent cultures
were obtained with strains showing reduced susceptibility to
phage therapy [157]. The second case report describes a 77year- old traumatic brain injury patient undergoing craniectomy
complicated by cerebritis and subdural and epidural empyemas.
Debridement was deemed necessary and intraoperative
cultures grew MDR A. baumannii. In addition to antibiotics,
the first dose of phage therapy was administered intravenously
on day 12 and continued for 8 days (98 intravenous
administrations). While the site of infection healed, the patient
did not clinically improve and family withdrew care on hospital
day 19 [156].

Conclusion

4.

5.

6.

7.

8.

9.

10.

Acinetobacter baumannii has the extraordinary adaptive
ability to develop resistance to overcome all treatment
options currently available. Despite the promising focus in
recent years on developing novel therapies, more real-world
experience in critically ill patients with invasive MDR A.
baumannii infections is needed to solidify a place in therapy for
one or more of these novel therapies. Moreover, many of these
novel antimicrobials have already demonstrated vulnerability
as reports of increasing MICs have been observed. Despite these
challenges, novel treatment modalities for MDR A. baumannii
are encouraging, yet further advances will be required as the era
of antimicrobial resistance continues.

Declarations of Potential Conflict of
Interest

11.

12.

13.

The authors declare that they have no competing interests.

14.

Funding

15.

The authors received no specific funding for this work.

References
1.

2.

3.

16.

Lynch JP 3rd, Zhanel GG, Clark NM. Infections due to
Acinetobacter baumannii in the ICU: treatment options.
Semin Respir Crit Care Med. 2017 Jun;38(3):311–25.
Rhomberg PR, Jones RN. Summary trends for the
Meropenem Yearly Susceptibility Test Information
Collection Program: a 10-year experience in the United
States (1999-2008). Diagn Microbiol Infect Dis. 2009
Dec;65(4):414–26.
Centers for Disease Control and Prevention (US). Antibiotic

17.

resistance threats in the United States, 2013. Centres for
Disease Control and Prevention, US Department of Health
and Human Services; 2013.
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert
D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An
update from the Infectious Diseases Society of America.
Clin Infect Dis. 2009 Jan;48(1):1–12.
Alfouzan WA, Noel AR, Bowker KE, Attwood ML,
Tomaselli SG, MacGowan AP. Pharmacodynamics of
minocycline against Acinetobacter baumannii studied in
a pharmacokinetic model of infection. Int J Antimicrob
Agents. 2017 Dec;50(6):715–7.
Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu
JW, et al. A multicenter study of risk factors and outcome
of hospitalized patients with infections due to carbapenemresistant Acinetobacter baumannii. Int J Infect Dis. 2010
Sep;14(9):e764–9.
Playford EG, Craig JC, Iredell JR. Carbapenemresistant Acinetobacter baumannii in intensive care unit
patients: risk factors for acquisition, infection and their
consequences. J Hosp Infect. 2007 Mar;65(3):204–11.
World Health Organization. WHO publishes priority
list of antibiotic-resistant pathogens. WHO Drug Inf.
2017;31(1):46.
Simpkin VL, Renwick MJ, Kelly R, Mossialos E.
Incentivising innovation in antibiotic drug discovery
and development: progress, challenges and next steps. J
Antibiot (Tokyo). 2017 Dec;70(12):1087–96.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y,
Falagas ME, Giske CG, et al. Multidrug-resistant,
extensively drug-resistant and pandrug-resistant bacteria:
an international expert proposal for interim standard
definitions for acquired resistance. Clin Microbiol Infect.
2012 Mar;18(3):268–81.
Peleg AY, Seifert H, Paterson DL. Acinetobacter
baumannii: emergence of a successful pathogen. Clin
Microbiol Rev. 2008 Jul;21(3):538–82.
Nowak J, Zander E, Stefanik D, Higgins PG, Roca I,
Vila J, et al. MagicBullet Working Group WP4. High
incidence of pandrug-resistant Acinetobacter baumannii
isolates collected from patients with ventilator-associated
pneumonia in Greece, Italy and Spain as part of the
MagicBullet clinical trial. J Antimicrob Chemother. 2017
Dec;72(12):3277–82.
Bonomo RA, Szabo D. Mechanisms of multidrug resistance
in Acinetobacter species and Pseudomonas aeruginosa.
Clin Infect Dis. 2006 Sep 1;43(Supplement_2):S49-56.
Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter
baumannii: from bench to bedside. World J Clin Cases.
2014 Dec;2(12):787–814.
Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, et
al. Biology of Acinetobacter baumannii: pathogenesis,
antibiotic resistance mechanisms, and prospective
treatment options. Front Cell Infect Microbiol. 2017
Mar;7:55.
Castanheira M, Mendes RE, Jones RN. Update on
Acinetobacter species: mechanisms of antimicrobial
resistance and contemporary in vitro activity of
minocycline and other treatment options. Clin Infect Dis.
2014 Dec 1;59(suppl_6):S367-73.
Vilacoba E, Almuzara M, Gulone L, Traglia GM, Figueroa
SA, Sly G, et al. Emergence and spread of plasmid-borne
tet(B):ISCR2 in minocycline-resistant Acinetobacter
baumannii isolates. Antimicrob Agents Chemother. 2013
Jan;57(1):651–4.

ULJRI Vol 3, (2) 2019

9

18. Wang P, McElheny CL, Mettus RT, Shanks RM, Doi Y.
Contribution of the TetB efflux pump to minocycline
susceptibility among carbapenem-resistant Acinetobacter
baumannii strains. Antimicrob Agents Chemother. 2017
Sep;61(10):e01176-17.
19. He X, Lu F, Yuan F, Jiang D, Zhao P, Zhu J, et al. Biofilm
formation caused by clinical Acinetobacter baumannii
isolates is associated with overexpression of the AdeFGH
Efflux Pump. Antimicrob Agents Chemother. 2015
Aug;59(8):4817–25.
20. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano
B, et al. Acinetobacter baumannii bloodstream infection
while receiving tigecycline: a cautionary report. J
Antimicrob Chemother. 2007 Jan;59(1):128–31.
21. Moffatt JH, Harper M, Harrison P, Hale JD,
Vinogradov E, Seemann T, et al. Colistin resistance in
Acinetobacter baumannii is mediated by complete loss
of lipopolysaccharide production. Antimicrob Agents
Chemother. 2010 Dec;54(12):4971–7.
22. Duarte A, Ferreira S, Almeida S, Domingues FC. Clinical
isolates of Acinetobacter baumannii from a Portuguese
hospital: PFGE characterization, antibiotic susceptibility
and biofilm-forming ability. Comp Immunol Microbiol
Infect Dis. 2016 Apr;45:29–33.
23. Eze EC, Chenia HY, El Zowalaty ME. Acinetobacter
baumannii biofilms: effects of physicochemical factors,
virulence, antibiotic resistance determinants, gene
regulation, and future antimicrobial treatments. Infect
Drug Resist. 2018 Nov;11:2277–99.
24. Rhodes NJ, Cruce CE, O’Donnell JN, Wunderink RG,
Hauser AR. Resistance trends and treatment options in
Gram-negative ventilator-associated pneumonia. Curr
Infect Dis Rep. 2018 Mar;20(2):3.
25. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel
J, Kallen AJ, et al. Antimicrobial-resistant pathogens
associated
with
healthcare-associated
infections:
summary of data reported to the National Healthcare
Safety Network at the Centers for Disease Control and
Prevention, 2011-2014. Infect Control Hosp Epidemiol.
2016 Nov;37(11):1288–301.
26. Mehrad B, Clark NM, Zhanel GG, Lynch JP 3rd.
Antimicrobial resistance in hospital-acquired Gramnegative bacterial infections. Chest. 2015 May;147(5):1413–
21.
27. Xie R, Zhang XD, Zhao Q, Peng B, Zheng J. Analysis of
global prevalence of antibiotic resistance in Acinetobacter
baumannii infections disclosed a faster increase in OECD
countries. Emerg Microbes Infect. 2018 Mar;7(1):31–10.
28. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new
lessons on an old antibiotic. Clin Microbiol Infect. 2012
Jan;18(1):18–29.
29. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins
revisited. Clin Microbiol Rev. 2008 Jul;21(3):449–65.
30. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL,
Forrest A, et al. International Consensus Guidelines
for the Optimal Use of the Polymyxins: Endorsed by the
American College of Clinical Pharmacy (ACCP), European
Society of Clinical Microbiology and Infectious Diseases
(ESCMID), Infectious Diseases Society of America (IDSA),
International Society for Anti-infective Pharmacology
(ISAP), Society of Critical Care Medicine (SCCM), and
Society of Infectious Diseases Pharmacists (SIDP).
Pharmacotherapy. 2019 Jan;39(1):10–39.
31. Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation
RL. Colistin and polymyxin B dosage regimens against

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

Acinetobacter baumannii: differences in activity and the
emergence of resistance. Antimicrob Agents Chemother.
2016 Jun;60(7):3921–33.
Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP,
Massih RC, et al. Epidemiology, clinical characteristics
and outcomes of extensively drug-resistant Acinetobacter
baumannii infections among solid organ transplant
recipients. PLoS One. 2012;7(12):e52349.
Snitkin ES, Zelazny AM, Gupta J, Palmore TN, Murray
PR, Segre JA; NISC Comparative Sequencing Program.
Genomic insights into the fate of colistin resistance and
Acinetobacter baumannii during patient treatment.
Genome Res. 2013 Jul;23(7):1155–62.
Lim SM, Sime FB, Roberts J. Multidrug-resistant
Acinetobacter baumannii infections: current evidence on
treatment options and role of PK/PD in dose optimization.
Int J Antimicrob Agents. 2019 Mar 2.
Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance
of Acinetobacter baumannii: clinical reports, mechanisms
and antimicrobial strategies. J Antimicrob Chemother.
2012 Jul;67(7):1607–15.
Vazquez Guillamet C, Kollef MH. Acinetobacter
pneumonia: improving outcomes with early identification
and appropriate therapy. Clin Infect Dis. 2018
Oct;67(9):1455–62.
Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed
A, Shields RK, et al. Colistin-resistant Acinetobacter
baumannii: beyond carbapenem resistance. Clin Infect
Dis. 2015 May;60(9):1295–303.
Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates
A, Voutsinas D, et al. Risk factors and outcomes associated
with acquisition of colistin-resistant KPC-producing
Klebsiella pneumoniae: a matched case-control study. J
Clin Microbiol. 2010 Jun;48(6):2271–4.
Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS.
Ampicillin/sulbactam compared with polymyxins for the
treatment of infections caused by carbapenem-resistant
Acinetobacter spp. J Antimicrob Chemother. 2008
Jun;61(6):1369–75.
Zalts R, Neuberger A, Hussein K, Raz-Pasteur A,
Geffen Y, Mashiach T, et al. Treatment of carbapenemresistant Acinetobacter baumannii ventilator-associated
pneumonia:
retrospective
comparison
between
intravenous colistin and intravenous ampicillin-sulbactam.
Am J Ther. 2016 Jan-Feb;23(1):e78–85.
Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez
FJ, Barrero-Almodóvar AE, García-Garmendia JL,
Bernabeu-WittelI M, et al. Treatment of multidrugresistant Acinetobacter baumannii ventilator-associated
pneumonia (VAP) with intravenous colistin: a comparison
with imipenem-susceptible VAP. Clin Infect Dis. 2003
May;36(9):1111–8.
Beganovic M, Luther MK, Daffinee KE, LaPlante KL.
Biofilm prevention concentrations (BPC) of minocycline
compared to polymyxin B, meropenem, and amikacin
against Acinetobacter baumannii. Diagn Microbiol Infect
Dis. 2019 Jul;94(3):223–6.
Denys GA, Callister SM, Dowzicky MJ. Antimicrobial
susceptibility among Gram-negative isolates collected in
the USA between 2005 and 2011 as part of the Tigecycline
Evaluation and Surveillance Trial (T.E.S.T.). Ann Clin
Microbiol Antimicrob. 2013 Sep;12(1):24.
Hoban DJ, Reinert RR, Bouchillon SK, Dowzicky MJ.
Global in vitro activity of tigecycline and comparator
agents: Tigecycline Evaluation and Surveillance Trial

ULJRI Vol 3, (2) 2019

10

45.

46.

47.

48.

49.

50.

51.

52.

53.

54.

55.

56.

57.

58.

2004-2013. Ann Clin Microbiol Antimicrob. 2015
May;14(1):27.
Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM,
Mediavilla JR, et al. Informing antibiotic treatment
decisions: evaluating rapid molecular diagnostics to
identify susceptibility and resistance to carbapenems
against Acinetobacter spp. in PRIMERS III. J Clin
Microbiol. 2016 Dec;55(1):134–44.
Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and
clinical outcomes of carbapenem-resistant Acinetobacter
baumannii ventilator-associated pneumonia. J Intensive
Care Med. 2010 Nov-Dec;25(6):343–8.
Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik
O, Glumcher F, et al.; 311 Study Group. Comparison of
tigecycline with imipenem/cilastatin for the treatment of
hospital-acquired pneumonia. Diagn Microbiol Infect Dis.
2010 Oct;68(2):140–51.
Marchaim D, Pogue JM, Tzuman O, Hayakawa K, Lephart
PR, Salimnia H, et al. Major variation in MICs of tigecycline
in Gram-negative bacilli as a function of testing method. J
Clin Microbiol. 2014 May;52(5):1617–21.
Wayne PA. Clinical and Laboratory Standards Institute:
Performance standards for antimicrobial susceptibility
testing: 20th informational supplement. CLSI document
M100-S20. 2010.
Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. The emergence
of clinical resistance to tigecycline. Int J Antimicrob
Agents. 2013 Feb;41(2):110–6.
Ni W, Han Y, Zhao J, Wei C, Cui J, Wang R, et al.
Tigecycline treatment experience against multidrugresistant Acinetobacter baumannii infections: a systematic
review and meta-analysis. Int J Antimicrob Agents. 2016
Feb;47(2):107–16.
Evans BA, Hamouda A, Amyes SG. The rise of carbapenemresistant Acinetobacter baumannii. Curr Pharm Des.
2013;19(2):223–38.
Buisson Y, Tran Van Nhieu G, Ginot L, Bouvet P, Schill
H, Driot L, et al. Nosocomial outbreaks due to amikacinresistant tobramycin-sensitive Acinetobacter species:
correlation with amikacin usage. J Hosp Infect. 1990
Jan;15(1):83–93.
Barnes MD, Bethel CR, Rutter JD, Akker FV, Papp-Wallace
KM, Bonomo RA. The novel β-Lactamase inhibitor, ETX2514, in combination with sulbactam effectively inhibits
Acinetobacter baumannii. In Open forum infectious
diseases 2017 Oct 4 (Vol. 4, No. suppl_1, pp. S368-S368).
US: Oxford University Press.
Chen H, Liu Q, Chen Z, Li C. Efficacy of sulbactam for
the treatment of Acinetobacter baumannii complex
infection: A systematic review and meta-analysis. J Infect
Chemother. 2017 May;23(5):278–85.
Bae S, Kim MC, Park SJ, Kim HS, Sung H, Kim MN, et
al. In vitro synergistic activity of antimicrobial agents in
combination against clinical isolates of colistin-resistant
Acinetobacter baumannii. Antimicrob Agents Chemother.
2016 Oct;60(11):6774–9.
Chen Z, Chen Y, Fang Y, Wang X, Chen Y, Qi Q, et al. Metaanalysis of colistin for the treatment of Acinetobacter
baumannii infection. Sci Rep. 2015 Nov;5(1):17091.
Durante-Mangoni E, Signoriello G, Andini R, Mattei A,
De Cristoforo M, Murino P, et al. Colistin and rifampicin
compared with colistin alone for the treatment of serious
infections due to extensively drug-resistant Acinetobacter
baumannii: a multicenter, randomized clinical trial. Clin
Infect Dis. 2013 Aug;57(3):349–58.

59. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli
Y, Benattar YD, et al. Colistin alone versus colistin plus
meropenem for treatment of severe infections caused by
carbapenem-resistant Gram-negative bacteria: an openlabel, randomised controlled trial. Lancet Infect Dis. 2018
Apr;18(4):391–400.
60. Makris D, Petinaki E, Tsolaki V, Manoulakas E, Mantzarlis
K, Apostolopoulou O, et al. Colistin versus colistin
combined with ampicillin-sulbactam for multiresistant
Acinetobacter
baumannii
ventilator-associated
pneumonia treatment: an open-label prospective study.
Indian J Crit Care Med. 2018 Feb;22(2):67–77.
61. Sirijatuphat R, Thamlikitkul V. Preliminary study of
colistin versus colistin plus fosfomycin for treatment
of carbapenem-resistant Acinetobacter baumannii
infections. Antimicrob Agents Chemother. 2014
Sep;58(9):5598–601.
62. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E,
Terzi A, et al. Colistin vs. the combination of colistin
and rifampicin for the treatment of carbapenemresistant Acinetobacter baumannii ventilator-associated
pneumonia. Epidemiol Infect. 2013 Jun;141(6):1214–22.
63. Cheng IL, Chen YH, Lai CC, Tang HJ. Intravenous
colistin monotherapy versus combination therapy against
carbapenem-resistant Gram-negative bacteria infections:
meta-analysis of randomized controlled trials. J Clin Med.
2018 Aug;7(8):208.
64. Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM,
et al. Clinical outcomes of tigecycline in the treatment of
multidrug-resistant Acinetobacter baumannii infection.
Yonsei Med J. 2012 Sep;53(5):974–84.
65. Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI,
Aydemir S, Bacakoglu F. Is tigecyclin a good choice in the
treatment of multidrug-resistant Acinetobacter baumannii
pneumonia? J Chemother. 2011 Dec;23(6):345–9.
66. Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y,
et al. Comparable efficacy of tigecycline versus colistin
therapy for multidrug-resistant and extensively drugresistant Acinetobacter baumannii pneumonia in critically
ill patients. PLoS One. 2016 Mar;11(3):e0150642.
67. Lee YT, Tsao SM, Hsueh PR. Clinical outcomes of tigecycline
alone or in combination with other antimicrobial agents
for the treatment of patients with healthcare-associated
multidrug-resistant Acinetobacter baumannii infections.
Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1211–20.
68. Jean SS, Hsieh TC, Hsu CW, Lee WS, Bai KJ, Lam C.
Comparison of the clinical efficacy between tigecycline
plus extended-infusion imipenem and sulbactam plus
imipenem against ventilator-associated pneumonia with
pneumonic extensively drug-resistant Acinetobacter
baumannii bacteremia, and correlation of clinical efficacy
with in vitro synergy tests. J Microbiol Immunol Infect.
2016 Dec 1;49(6):924-33.
69. He H, Zheng Y, Sun B, Tang X, Wang R, Tong Z. Tigecycline
combination for ventilator-associated pneumonia caused
by extensive drug-resistant Acinetobacter baumannii. J
Thorac Dis. 2016 Oct;8(10):2784–92.
70. Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC.
Antibiotic strategies and clinical outcomes in critically ill
patients with pneumonia caused by carbapenem-resistant
Acinetobacter baumannii. Clin Microbiol Infect. 2018
Aug;24(8):908.e1–7.
71. Goff DA, Bauer KA, Mangino JE. Bad bugs need old
drugs: a stewardship program’s evaluation of minocycline
for
multidrug-resistant
Acinetobacter
baumannii

ULJRI Vol 3, (2) 2019

11

72.

73.

74.

75.

76.

77.

78.

79.

80.

81.

82.

83.

84.

85.

infections. Clinical Infectious Diseases. 2014 Dec
1;59(suppl_6):S381-7.
Craig
WA.
Pharmacokinetic/pharmacodynamic
parameters: rationale for antibacterial dosing of mice and
men. Clin Infect Dis. 1998 Jan;26(1):1–10.
McKinnon PS, Paladino JA, Schentag JJ. Evaluation of
area under the inhibitory curve (AUIC) and time above
the minimum inhibitory concentration (T>MIC) as
predictors of outcome for cefepime and ceftazidime in
serious bacterial infections. Int J Antimicrob Agents. 2008
Apr;31(4):345–51.
Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova
T, et al. Clinical and microbiological efficacy of continuous
versus intermittent application of meropenem in critically
ill patients: a randomized open-label controlled trial. Crit
Care. 2012 Jun;16(3):R113.
Yu Z, Pang X, Wu X, Shan C, Jiang S. Clinical outcomes
of prolonged infusion (extended infusion or continuous
infusion) versus intermittent bolus of meropenem in
severe infection: A meta-analysis. PLoS One. 2018
Jul;13(7):e0201667.
Wang D. Experience with extended-infusion meropenem
in the management of ventilator-associated pneumonia
due to multidrug-resistant Acinetobacter baumannii. Int J
Antimicrob Agents. 2009 Mar;33(3):290–1.
Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek
ST, Kollef MH. Predictors of 30-day mortality and hospital
costs in patients with ventilator-associated pneumonia
attributed to potentially antibiotic-resistant Gramnegative bacteria. Chest. 2008 Aug;134(2):281–7.
Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley
J, McGovern PC. Randomized phase 2 trial to evaluate the
clinical efficacy of two high-dosage tigecycline regimens
versus imipenem-cilastatin for treatment of hospitalacquired pneumonia. Antimicrob Agents Chemother. 2013
Apr;57(4):1756–62.
De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R,
Bello G, et al. High dose tigecycline in critically ill patients
with severe infections due to multidrug-resistant bacteria.
Crit Care. 2014 May;18(3):R90.
Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden
A, Schweizer F, et al. Review of eravacycline, a
novel fluorocycline antibacterial agent. Drugs. 2016
Apr;76(5):567–88.
Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky
JA. In vitro activity of eravacycline against 2213 Gramnegative and 2424 Gram-positive bacterial pathogens
isolated in Canadian hospital laboratories: CANWARD
surveillance study 2014-2015. Diagn Microbiol Infect Dis.
2018 May;91(1):55–62.
Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro
activity of the novel fluorocycline eravacycline against
carbapenem non-susceptible Acinetobacter baumannii.
Int J Antimicrob Agents. 2018 Jan;51(1):62–4.
Livermore DM, Mushtaq S, Warner M, Woodford N. In
vitro activity of eravacycline against carbapenem-resistant
Enterobacteriaceae and Acinetobacter baumannii.
Antimicrob Agents Chemother. 2016 May;60(6):3840–4.
Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D,
Quale J. Activity of eravacycline against Enterobacteriaceae
and Acinetobacter baumannii, including multidrugresistant isolates, from New York City. Antimicrob Agents
Chemother. 2015 Mar;59(3):1802–5.
Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai
L, et al. Assessing the efficacy and safety of eravacycline vs

86.

87.

88.

89.

90.

91.

92.

93.

94.

95.

96.

97.

ertapenem in complicated intra-abdominal infections in
the investigating Gram-negative infections treated with
eravacycline (IGNITE 1) trial: a randomized clinical trial.
JAMA Surg. 2017 Mar;152(3):224–32.
Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N,
Stefanova P, Sutcliffe JA, et al. Phase 2, randomized, doubleblind study of the efficacy and safety of two dose regimens
of eravacycline versus ertapenem for adult communityacquired
complicated
intra-abdominal
infections.
Antimicrob Agents Chemother. 2014;58(4):1847–54.
Tetraphase Pharmaceuticals. Tetraphase announces
positive top-line results from phase 3 IGNITE4 clinical
trial in complicated intra-abdominal infections [press
release] (2017 Jul 25) [cited 2019 Sep 30]. Available
from: https://ir.tphase.com/news-releases/news-releasedetails/tetraphase-announces-positive-top-line-resultsphase-3-ignite4
ClinicalTrials.gov [Internet]. Bethesda (MD): National
Library of Medicine (US). 2000 Feb 29 - . Identifier
NCT03696550, A safety and PK study of IV eravacycline;
2018 Sep 26 [cited 2019 Sep 30]; [about 8 screens].
Available
from:
https://clinicaltrials.gov/ct2/show/
NCT03696550
Yue CS, Sutcliffe JA, Colucci P, Sprenger CR. Population
pharmacokinetic modeling of TP-434, a novel fluorocycline,
following single and multiple dose administration.
Abstract presented at: 50th Interscience Conference of
Antimicrobial Agents and Chemotherapy (ICAAC); 2010
Sep 12-15; Boston, MA.
Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4:
Results of a phase 3, randomized, multicenter, prospective
trial of eravacycline vs meropenem in the treatment of
complicated intraabdominal infections. Clin Infect Dis.
2018 Dec 1.
Tetraphase Pharmaceuticals. Tetraphase announces
top-line results from IGNITE3 phase 3 clinical trial of
eravacycline in complicated urinary tract infections (cUTI)
[press release] (2018 Feb 13) [cited 2018 Dec 18]. Available
from: https://ir.tphase.com/news-releases/news-releasedetails/tetraphase-announces-top-line-results-ignite3phase-3-clinical
Pfaller MA, Huband MD, Rhomberg PR, Flamm RK.
Surveillance of omadacycline activity against clinical
isolates from a global collection (North America,
Europe,
Latin
America,
Asia-Western
Pacific),
2010-2011. Antimicrob Agents Chemother. 2017
Apr;61(5):e00018–00017.
Pfaller MA, Huband MD, Shortridge D, Flamm RK.
Surveillance of omadacycline activity tested against clinical
isolates from the United States and Europe as part of
the 2016 SENTRY Antimicrobial Surveillance Program.
Antimicrob Agents Chemother. 2018 Mar;62(4):e02327-17.
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej
A, et al. Omadacycline for community-acquired bacterial
pneumonia. N Engl J Med. 2019 Feb;380(6):517–27.
O’Riordan W, Green S, Overcash JS, Puljiz I, Metallidis
S, Gardovskis J, et al. Omadacycline for acute bacterial
skin and skin-structure infections. N Engl J Med. 2019
Feb;380(6):528–38.
Xerava (eravacycline) for injection [package insert on the
Internet]. Watertown (MA): Tetraphase Pharmaceuticals,
2018 [revised 2018 Aug; cited 2018 Dec 18]. Available
from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2018/211109lbl.pdf
Tygacil (tigecycline) i.v. injection label [package insert on

ULJRI Vol 3, (2) 2019

12

98.

99.

100.

101.

102.

103.

104.

105.

106.

107.

108.

the Internet]. Philadelphia (PA): Wyeth Pharmaceuticals
Inc., 2010 [revised 2010 Jul; cited 2018 Dec 15]. Available
from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2010/021821s021lbl.pdf
Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA,
Sahm DF. In vitro activity of the siderophore cephalosporin,
cefiderocol, against carbapenem-nonsusceptible and
multidrug-resistant isolates of Gram-negative bacilli
collected worldwide in 2014 to 2016. Antimicrob Agents
Chemother. 2018 Jan;62(2):e01968-17.
Möllmann U, Heinisch L, Bauernfeind A, Köhler T,
Ankel-Fuchs D. Siderophores as drug delivery agents:
application of the “Trojan Horse” strategy. Biometals.
2009 Aug;22(4):615–24.
Aoki T, Yoshizawa H, Yamawaki K, Yokoo K, Sato
J, Hisakawa S, et al. Cefiderocol (S-649266), A new
siderophore cephalosporin exhibiting potent activities
against Pseudomonas aeruginosa and other Gramnegative pathogens including multi-drug resistant
bacteria: structure activity relationship. Eur J Med Chem.
2018 Jul;155:847–68.
Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA,
Sahm DF. In vitro activity of the siderophore cephalosporin,
cefiderocol, against a recent collection of clinically relevant
Gram- negative bacilli from North America and Europe,
including carbapenem-nonsusceptible isolates (SIDEROWT-2014 Study). Antimicrob Agents Chemother. 2017
Aug;61(9):e00093-17.
Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R,
Sahm DF. In vitro activity of cefiderocol, a siderophore
cephalosporin, against Gram-negative bacilli isolated by
clinical laboratories in North America and Europe in 20152016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019
Apr;53(4):456–66.
Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR.
In vitro activities of cefiderocol, ceftolozane/tazobactam,
ceftazidime/avibactam and other comparative drugs
against imipenem-resistant Pseudomonas aeruginosa
and Acinetobacter baumannii, and Stenotrophomonas
maltophilia, all associated with bloodstream infections in
Taiwan. J Antimicrob Chemother. 2019 Feb;74(2):380–6.
Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y,
Echols R, et al. In vitro activity of cefiderocol, a siderophore
cephalosporin, against a recent collection of clinically
relevant carbapenem-non-susceptible Gram-negative
bacilli, including serine carbapenemase- and metallo-βlactamase-producing isolates (SIDERO-WT-2014 Study).
Int J Antimicrob Agents. 2019 Feb;53(2):177–84.
Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ; Hellenic
Cefiderocol Study Group. Activity of cefiderocol (S649266) against carbapenem-resistant Gram-negative
bacteria collected from inpatients in Greek hospitals. J
Antimicrob Chemother. 2017 Jun;72(6):1704–8.
Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg
JK, Galloway C. Cefiderocol, a siderophore cephalosporin
for Gram-negative bacterial infections; pharmacokinetics
and safety in subjects with renal impairment. J Clin
Pharmacol. 2017 May;57(5):584–91.
Portsmouth S, van Veenhuyzen D, Echols R, Machida M,
Ferreira JC, Ariyasu M, et al. Cefiderocol versus imipenemcilastatin for the treatment of complicated urinary tract
infections caused by Gram-negative uropathogens: a phase
2, randomised, double-blind, non-inferiority trial. Lancet
Infect Dis. 2018 Dec;18(12):1319–28.
Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B,

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

Bifulco N, Huynh H, et al. ETX2514 is a broad-spectrum
β-lactamase inhibitor for the treatment of drug-resistant
Gram-negative
bacteria
including
Acinetobacter
baumannii. Nat Microbiol. 2017 Jun;2(9):17104.
Mushtaq S, Vickers A, Woodford N, Livermore DM.
WCK 4234, a novel diazabicyclooctane potentiating
carbapenems against Enterobacteriaceae, Pseudomonas
and Acinetobacter with class A, C and D β-lactamases. J
Antimicrob Chemother. 2017 Jun;72(6):1688–95.
McLeod SM, Shapiro AB, Moussa SH, Johnstone M,
McLaughlin RE, de Jonge BL, et al. Frequency and
mechanism of spontaneous resistance to sulbactam
combined with the novel β-lactamase inhibitor ETX2514 in
clinical isolates of Acinetobacter baumannii. Antimicrob
Agents Chemother. 2018 Jan;62(2):e01576-17.
Tetraphase Pharmaceuticals. Tetraphase announces
top-line results from IGNITE2 phase 3 clinical trial of
eravacycline in cUTI [press release] (2015 Sep 8) [cited
2019 Sep 30]. Available from: https://ir.tphase.com/newsreleases/news-release-details/tetraphase-announces-topline-results-ignite2-phase-3-clinical
Tetraphase Pharmaceuticals. Tetraphase Pharmaceuticals
announces positive phase 1 single-ascending dose data for
antibiotic pipeline candidates [press release] (2017 Jun
5) [cited 2019 Sep 30]. Available from: https://ir.tphase.
com/news-releases/news-release-details/tetraphasepharmaceuticals-announces-positive-phase-1-single
Grossman TH, Fyfe C, O’Brien W, et al. Fluorocycline TP271 is potent against complicated community-acquired
bacterial pneumonia pathogens. mSphere. 2017 Feb;22;(2)
e00004-17.
Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized,
double-blind, placebo-controlled studies of the safety and
pharmacokinetics of single and multiple ascending doses
of eravacycline. Antimicrob Agents Chemother. 2018
Oct;62(11):e01174–01118.
ClinicalTrials.gov [Internet]. Bethesda (MD): National
Library of Medicine (US). 2000 Feb 29 - . Identifier
NCT03450187, A phase 1 TP-271 oral PK multiple
ascending dose study; 2018 Feb 16 [cited 2019 Sep 30];
[about 10 screens]. Available from: https://clinicaltrials.
gov/ct2/show/NCT03450187
ClinicalTrials.gov [Internet]. Bethesda (MD): National
Library of Medicine (US). 2000 Feb 29 - . Identifier
NCT03024034, A phase 1 TP-271 oral PK single ascending
dose study; 2017 Jan 9 [cited 2019 Sep 30]; [about 8
screens]. Available from: https://clinicaltrials.gov/ct2/
show/NCT03024034
Falagas ME, Skalidis T, Vardakas KZ, Voulgaris GL,
Papanikolaou G, Legakis N; Hellenic TP-6076 Study
Group. Activity of TP-6076 against carbapenem-resistant
Acinetobacter baumannii isolates collected from
inpatients in Greek hospitals. Int J Antimicrob Agents.
2018 Aug;52(2):269–71.
Grossman TH, Fyfe C, Kerstein K, Xiao X, Sun C, Newman
J, Nguyen P, Pulse M, Weiss WJ, Dumas J, Sutcliffe JA.
TP-6076 is efficacious in a mouse pneumonia model
with carbapenem-resistant Acinetobacter baumannii
(CRAB) and retains potency against common tetracyclineresistance mechanisms. Poster presented at: 26th
European Congress of Clinical Microbiology and Infectious
Diseases (ECCMID); 2016 Apr 9-12; Amsterdam,
Netherlands.
Seifert H, Stefanik D, Sutcliffe J, Higgins PG. In-vitro
activity of the novel fluorocycline TP-6076 against

ULJRI Vol 3, (2) 2019

13

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

carbapenem non-susceptible Acinetobacter baumannii.
Poster presented at: 27th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID); 2017 Apr
22-25; Vienna, Austria.
Fyfe C, Close B, LeBlanc G, Newman J. TP-6076 is
active against carbapenem- and polymyxin-resistant
Enterobacteriaceae and Acinetobacter baumannii isolates
in the FDA-CDC antimicrobial isolate bank panels.
Abstract presented at: 27th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID); 2017 Apr
22-25; Vienna, Austria.
Tsai L, Moore A. Safety, tolerability and pharmacokinetics
of multiple doses of TP-6076, a novel, fully synthetic
tetracycline, in a phase 1 study. In Open Forum Infect Dis.
2018 Nov; 5(Suppl 1): S420.
ClinicalTrials.gov [Internet]. Bethesda (MD): National
Library of Medicine (US). 2000 Feb 29 - . Identifier
NCT03691584, Phase 1, safety and bronchopulmonary
PK study in healthy volunteers (BAL); 2018 Sep 27 [cited
2019 Sep 30]; [about 6 screens]. Available from: https://
clinicaltrials.gov/ct2/show/NCT03691584
Daigle D, Hamrick J, Chatwin C, Kurepina N, Kreiswirth
BN, Shields RK, et al. 1370. Cefepime/VNRX-5133 broadspectrum activity is maintained against emerging KPC-and
PDC-variants in multidrug-resistant K. pneumoniae and P.
aeruginosa. In Open Forum Infect Dis. 2018 Nov(Suppl 1):
S419-S420.
Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, PappWallace KM, et al. Potent β-lactam enhancer activity
of zidebactam and WCK 5153 against Acinetobacter
baumannii,
including
carbapenemase-producing
clinical isolates. Antimicrob Agents Chemother. 2017
Oct;61(11):e01238–01217.
Sader HS, Castanheira M, Huband M, Jones RN, Flamm
RK. WCK 5222 (cefepime-zidebactam) antimicrobial
activity against clinical isolates of Gram-negative
bacteria collected worldwide in 2015. Antimicrob Agents
Chemother. 2017 Apr;61(5):e00072-17.
Avery LM, Abdelraouf K, Nicolau DP. Assessment of the in
vivo efficacy of WCK 5222 (cefepime-zidebactam) against
carbapenem-resistant Acinetobacter baumannii in the
neutropenic murine lung infection model. Antimicrob
Agents Chemother. 2018 Oct;62(11):e00948–00918.
Preston RA, Mamikonyan G, DeGraff S, Chiou J,
Kemper CJ, Xu A, et al. Single-Center Evaluation of the
Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam
Combination) in Subjects with Renal Impairment.
Antimicrob Agents CH. 2019 Jan 1;63(1):e01484-18.
Chugh R, Lakdavala F, Friedland HD, Bhatia A. Safety and
pharmacokinetics of multiple ascending doses of WCK 5107
(zidebactam) and WCK 5222 (cefepime and zidebactam).
Poster presented at: 27th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID); 2017 Apr
22-25; Vienna, Austria.
Rodvold KA, Gotfried MH, Chugh R, Gupta M, Patel
A, Chavan R, et al. Plasma and intrapulmonary
concentrations of cefepime and zidebactam following
intravenous administration of WCK 5222 to healthy
adult subjects. Antimicrob Agents Chemother. 2018
Jul;62(8):e00682–00618.
AiCuris Pharmaceuticals. AiCuris initiates clinical
development of AIC499, a novel resistance-breaking
antibiotic against a broad range of MDR Gram-negative
bacteria [press release] (2017 Jan 4) [cited 2019 Sep 30].
Available from: http://www.aicuris.com/74n93AiCuris-

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

141.

142.

143.

Initiates-Clinical-Development-of-AIC499,-a-NovelResistance-Breaking-Antibiotic-against-a-Broad-Rangeof-MDR-Gram-Negative-Bacteria.htm
Hackel M, Butler D, Miller LG, Bouchillon SK, Sahm DF. In
vitro antibacterial activity of GSK3342830 against a global
collection of clinically relevant Gram-negative bacteria.
Am Soc Microbiol. 2017 Jun:1-5.
Tenero D, Farinola N, Berkowitz E, Tiffany CA, Qian Y,
Xue Z, et al. Pharmacokinetics, safety, and tolerability
evaluation of single and multiple doses of GSK3342830
in healthy volunteers. Clin Pharmacol Drug Dev.
2018;cpdd.637.; Epub ahead of print.
Zurawski DV, Reinhart AA, Alamneh YA, Pucci MJ, Si
Y, Abu-Taleb R, et al. SPR741, an antibiotic adjuvant,
potentiates the in vitro and in vivo activity of rifampin
against clinically relevant extensively drug-resistant
Acinetobacter baumannii. Antimicrob Agents Chemother.
2017 Nov;61(12):e01239–01217.
Warn P, Teague J, Corbett D, Payne L, Burgess E,
Lister T, Parr T. In-vivo efficacy of combinations of
novel antimicrobial peptide SPR741 and rifampicin in
neutropenic murine pneumonia models of Gram-negative
bacterial infections. Abstract presented at: 27th European
Congress of Clinical Microbiology and Infectious Diseases
(ECCMID); 2017 Apr 22-25; Vienna, Austria.
Utley L, Lister T, Coleman S, Eckburg P. Determination
of the pharmacokinetics of single (SAD) and multiple
ascending doses (MAD) of SPR741 in healthy volunteers.
Abstract presented at: 28th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID); 2018
Apr 21-24; Madrid, Spain.
ClinicalTrials.gov [Internet]. Bethesda (MD): National
Library of Medicine (US). 2000 Feb 29 - . Identifier
NCT03376529, Phase 1 study to evaluate DDI, PK, safety,
tolerability of SPR741; 2017 Dec 5 [cited 2019 Sep 30];
[about 9 screens]. Available from: https://clinicaltrials.
gov/ct2/show/NCT03376529
ClinicalTrials.gov [Internet]. Bethesda (MD): National
Library of Medicine (US). 2000 Feb 29 - . Identifier
NCT03022175, A first in human study of the safety and
tolerability of single and multiple doses of SPR741 in
healthy volunteers; 2016 Dec 16 [cited 2019 Sep 30];
[about 7 screens]. Available from: https://clinicaltrials.
gov/ct2/show/NCT03022175
Wang-Lin SX, Balthasar JP. Pharmacokinetic and
pharmacodynamic considerations for the use of
monoclonal antibodies in the treatment of bacterial
infections. Antibodies (Basel). 2018 Jan;7(1):5.
Motley MP, Fries BC. A new take on an old remedy:
generating antibodies against multidrug-resistant Gramnegative bacteria in a postantibiotic world. MSphere. 2017
Oct;2(5):e00397–00317.
McConnell MJ, Rumbo C, Bou G, Pachón J. Outer membrane
vesicles as an acellular vaccine against Acinetobacter
baumannii. Vaccine. 2011 Aug;29(34):5705–10.
McConnell MJ, Pachón J. Active and passive immunization
against Acinetobacter baumannii using an inactivated
whole cell vaccine. Vaccine. 2010 Dec;29(1):1–5.
Huang W, Yao Y, Long Q, Yang X, Sun W, Liu C, et al.
Immunization against multidrug-resistant Acinetobacter
baumannii effectively protects mice in both pneumonia
and sepsis models. PLoS One. 2014 Jun;9(6):e100727.
Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD,
St Michael F, et al. The K1 capsular polysaccharide from
Acinetobacter baumannii is a potential therapeutic

ULJRI Vol 3, (2) 2019

14

144.

145.

146.

147.

148.

149.

150.

151.

152.

target via passive immunization. Infect Immun. 2013
Mar;81(3):915–22.
Nielsen TB, Pantapalangkoor P, Luna BM, Bruhn KW,
Yan J, Dekitani K, et al. Monoclonal antibody protects
against Acinetobacter baumannii infection by enhancing
bacterial clearance and evading sepsis. J Infect Dis. 2017
Aug;216(4):489–501.
Nwokoro E, Leach R, Årdal C, Baraldi E, Ryan K, Plahte
J. An assessment of the future impact of alternative
technologies on antibiotics markets. J Pharm Policy Pract.
2016 Oct;9(1):34.
Doss J, Culbertson K, Hahn D, Camacho J, Barekzi N.
A review of phage therapy against bacterial pathogens
of aquatic and terrestrial organisms. Viruses. 2017
Mar;9(3):50.
El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly
RF. A systematic and critical review of bacteriophage
therapy against multi-drug resistant ESKAPE organisms in
humans. Clin Infect Dis. 2018.
Knezevic P, Curcin S, Aleksic V, Petrusic M, Vlaski L.
Phage-antibiotic synergism: a possible approach to
combatting Pseudomonas aeruginosa. Res Microbiol.
2013 Jan;164(1):55–60.
Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z. Phage
therapy in bacterial infections treatment: one hundred
years after the discovery of bacteriophages. Curr Microbiol.
2017 Feb;74(2):277–83.
Cha K, Oh HK, Jang JY, Jo Y, Kim WK, Ha GU, et al.
Characterization of two novel bacteriophages infecting
multidrug- resistant (MDR) Acinetobacter baumannii
and evaluation of their therapeutic efficacy in vivo. Front
Microbiol. 2018 Apr;9:696.
Jeon J, D’Souza R, Pinto N, Ryu CM, Park J, Yong D, et
al. Characterization and complete genome sequence
analysis of two Myoviral bacteriophages infecting clinical
carbapenem-resistant Acinetobacter baumannii isolates. J
Appl Microbiol. 2016 Jul;121(1):68–77.
Jeon J, Ryu CM, Lee JY, Park JH, Yong D, Lee K. In vivo
application of bacteriophage as a potential therapeutic
agent to control OXA-66-like carbapenemase-producing
Acinetobacter baumannii strains belonging to sequence
type 357. Appl Environ Microbiol. 2016 Jun;82(14):4200-

8.
153. Kusradze I, Karumidze N, Rigvava S, Dvalidze T, Katsitadze
M, Amiranashvili I, et al. Characterization and testing the
efficiency of Acinetobacter baumannii phage vB-GEC_AbM-G7 as an antibacterial agent. Front Microbiol. 2016
Oct;7:1590.
154. Shivaswamy VC, Kalasuramath SB, Sadanand CK,
Basavaraju AK, Ginnavaram V, Bille S, et al. Ability
of bacteriophage in resolving wound infection caused
by multidrug-resistant Acinetobacter baumannii in
uncontrolled diabetic rats. Microb Drug Resist. 2015
Apr;21(2):171–7.
155. Hua Y, Luo T, Yang Y, et al. Phage therapy as a promising
new treatment for lung infection caused by carbapenemresistant Acinetobacter baumannii in mice. Front
Microbiol. 2018;8:2659.
156. LaVergne S, Hamilton T, Biswas B, Kumaraswamy M,
Schooley RT, Wooten D. Phage therapy for a multidrugresistant Acinetobacter baumannii craniectomy site
infection. Open Forum Infect Dis. 2018 Mar;5(4):ofy064.
157. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A,
Lancaster J, Lessor L, et al. Development and use of
personalized bacteriophage-based therapeutic cocktails to
treat a patient with a disseminated resistant Acinetobacter
baumannii infection. Antimicrob Agents Chemother. 2017
Sep;61(10):e00954-17.
158. Bassetti M, Corey R, Doi Y, Morrissey I, Grossman T,
Olesky M, Sutcliffe J. In Vitro Global Surveillance of
Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-resistant (MDR) Isolates, Over
a Three-year Period (2013-15). Poster presented at: IDWeek 2016; 2016 Oct 26-30; New Orleans, LA.
159. Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial
activity of eravacycline (TP-434), a novel fluorocycline,
against hospital and community pathogens. Antimicrob
Agents Chemother. 2013 Nov;57(11):5548–58.
160. Tsuji M, Hackel M, Echols R, Yamano Y, Sahm DF. In
vitro activity of cefiderocol against globally collected
carbapenem-resistant Gram-negative bacteria isolated
from urinary tract source: SIDERO-CR-2014/2016. In
Open Forum Infect Dis. 2018 Nov(Suppl 1): S366.

ULJRI Vol 3, (2) 2019

15

